Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/20/26
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewsWire • 11/24/25
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 11/13/25
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/03/25
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 08/13/25
Aura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsGlobeNewsWire • 05/15/25
Aura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewsWire • 05/15/25
Aura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 05/15/25
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsGlobeNewsWire • 04/02/25
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)Seeking Alpha • 03/25/25
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewsWire • 03/24/25
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology CongressGlobeNewsWire • 03/24/25
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology CongressGlobeNewsWire • 03/03/25
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGenGlobeNewsWire • 12/02/24
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade DiseaseBenzinga • 10/18/24
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialGlobeNewsWire • 10/17/24
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +Seeking Alpha • 09/20/24
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer StudyZacks Investment Research • 09/13/24
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal MelanomaGlobeNewsWire • 09/12/24
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024GlobeNewsWire • 09/03/24